ESTRO 2024 - Abstract Book

S2374

Clinical - Urology

ESTRO 2024

Conclusion:

Previously defined recruitment goals were met. Conducting a randomized study in this scenario is feasible. Acute gastrointestinal and genitourinary toxicity are low and appears to be lower in the 2-fraction schedule; differences between groups need to be elucidated. IPSS showed an increase through treatment in both groups, with no subsequent increase. Longer follow-up is required to asses long-term toxicity and efficacy.

Keywords: Prostate cancer, SBRT, Ultrahypofractionated

References:

1. Lewis M, Bromley K, Sutton CJ et al. Determining sample size for progression criteria for pragmatic pilot RCTs: the hypothesis test strikes back!. Pilot Feasibility Stud 7, 40 (2021). doi: 10.1186/s40814-021-00770-x.

2. National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Published May 28, 2009; Revised Version 4.03 June 14, 2010. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf.

3. French B, Shotwell MS. Regression Models for Ordinal Outcomes. JAMA. 328(8):772-773 (2022). doi: 10.1001/jama.2022.12104.

4. Geissinger EA, Khoo CLL, Richmond IC, Faulkner SJM, Schneider DC. A Case for Beta Regression in the Natural Sciences. Ecosphere 13(2): e3940 (2022). doi: 10.1002/ecs2.3940.

922

Digital Poster

Does an endorectal balloon stabilize the prostate position during online adaptive MRIgRT?